Equities

Catalent Inc

Catalent Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)60.11
  • Today's Change-0.21 / -0.35%
  • Shares traded1.98m
  • 1 Year change+26.49%
  • Beta1.1568
Data delayed at least 15 minutes, as of Sep 19 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Jun 30 2024202420232022
ASSETS
Cash And Short Term Investments289280538
Total Receivables, Net1,5061,4011,449
Total Inventory603801724
Prepaid expenses151168135
Other current assets, total484270
Total current assets2,5972,6922,916
Property, plant & equipment, net3,7203,7413,220
Goodwill, net2,3333,0393,006
Intangibles, net8419801,060
Long term investments------
Note receivable - long term------
Other long term assets242252219
Total assets9,75310,77710,507
LIABILITIES
Accounts payable361424421
Accrued expenses356359385
Notes payable/short-term debt000
Current portion long-term debt/capital leases4853631
Other current liabilities, total266211235
Total current liabilities1,0311,5301,072
Total long term debt4,8574,3134,171
Total debt4,9054,8494,202
Deferred income tax5.0076202
Minority interest------
Other liabilities, total256247267
Total liabilities6,1496,1665,712
SHAREHOLDERS EQUITY
Common stock2.002.002.00
Additional paid-in capital4,7874,7014,649
Retained earnings (accumulated deficit)(781)262538
Treasury stock - common------
Unrealized gain (loss)--0(4)
Other equity, total(404)(354)(390)
Total equity3,6044,6114,795
Total liabilities & shareholders' equity9,75310,77710,507
Total common shares outstanding180180179
Treasury shares - common primary issue1.0000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.